Bullish case
$285 to $300
More likely if oncology medicines maintain strong growth, late-stage trials and launches remain productive, the Wainua setback stays contained, 2026 guidance is delivered, and investors maintain a premium earnings multiple.
AstraZeneca PLC research snapshot
AZN AI Stock Analysis
AZN AI stock analysis currently reads AstraZeneca as a large global biopharma company with an oncology-led growth engine, broad late-stage pipeline, strong cash generation, and a higher near-term risk profile after the Wainua CARDIO-TTRansform Phase III setback. At the July 10, 2026 data cutoff, AZN last closed near $178.49 with a verified market capitalization near $277.49 billion. This page uses scenarios, technical levels, and source-backed data for informational research, not investment advice.
Current price
$178.49
Market cap
$277.49 billion
AI score
69 / 100
Rating
High-quality oncology franchise, clinical-event risk elevated
Trend status
Long-term trend near flat with a sharp event-driven reset
Data cutoff (updated weekly)
July 10, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. AstraZeneca has detailed annual filings, quarterly results, a broad investor base, industry coverage, and numerous independent market-data sources.
- bias Check
- The main AI bias risk is repeating the oncology growth narrative while overlooking binary trial outcomes, pricing and reimbursement pressure, China exposure, patent loss, pipeline spending, and debt. The Wainua study miss is a direct reminder that a deep pipeline does not remove clinical risk.
- ai Confidence
- High for FY2025 reported results, Q1 2026 results, market-cap math, and valuation arithmetic. Medium for technical levels and forward valuation because clinical news and market multiples can reset quickly.
- investment Certainty
- Medium-low. The business quality and growth ambition are visible, but the appropriate margin of safety depends on the durability of the oncology franchise and the outcome of pipeline, policy, and pricing risks.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | AstraZeneca sells specialty medicines across oncology, biopharmaceuticals, rare disease, and vaccines and immunotherapies, with oncology as the largest growth driver. | High |
| Moat | Patents, clinical evidence, regulatory capability, physician relationships, manufacturing scale, and a global commercial network support the moat, but each medicine eventually faces competition. | Medium-high |
| Management | Pascal Soriot and the leadership team have built a large oncology and rare-disease portfolio; execution should be judged by pipeline productivity, disciplined business development, and returns on high R&D spending. | Medium-high |
| Financial trend | FY2025 revenue rose 8.6% to $58.739 billion and reported EPS rose 45% to $6.60. Q1 2026 revenue was $15.29 billion and adjusted EPS was $2.58. | High |
| Valuation | At the $178.49 July 9 close, AZN was about 27.0x FY2025 reported EPS and 24.5x trailing free cash flow per share. The multiple requires sustained portfolio execution. | Medium-high |
| Technical trend | The July 10 event-driven selloff left AZN below 50-day and 200-day moving-average snapshots near $183, with RSI near 40 and the short-term setup weakened. | Medium |
| Risk level | Risk is elevated by clinical trial outcomes, patent cliffs, drug pricing, regulatory actions, China exposure, currency, debt, and large research commitments. | High |
| AI confidence | The data record is strong, but AI cannot turn clinical uncertainty or market sentiment into a dependable price prediction. | High data confidence |
| Investment certainty | Medium-low certainty. AstraZeneca has clear franchise strength, but investors still need a price and risk tolerance that can absorb binary pipeline news. | Medium-low |
AZN AI stock forecast
AZN AI Stock Forecast Scenarios
The AZN AI stock forecast uses scenario math around the $178.49 July 9 close and FY2025 core EPS of $9.16. The audited three-year framework produced a bearish area near $149, a base area near $220, and a bullish area near $293 before dividends.
Base case
$210 to $230
More likely if core EPS compounds around 10% annually, the portfolio absorbs normal patent and pricing pressure, and the market values AZN near an 18x earnings multiple.
Bearish case
$140 to $155
More likely if more pipeline programs disappoint, oncology growth decelerates, pricing or China pressures rise, debt limits flexibility, or the market compresses the earnings multiple toward 14x.
AZN AI technical analysis
AZN AI Technical Analysis
AZN AI technical analysis is cautious as of the July 10, 2026 cutoff. StockAnalysis placed the 50-day average near $183.67, the 200-day average near $183.16, and RSI near 39.68 after the Wainua trial-related decline. These levels are snapshots, not forecasts.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $178.49 | July 9 closing price used for market-cap and valuation math. July 10 intraday trading was lower after the clinical update. |
| Near support | $171 to $172 | The July 10 intraday low was $171.42. A sustained break below this zone would extend the event-driven downtrend. |
| Near resistance | $178 to $179 | The July 9 closing area is the first rebound test after the gap lower. |
| 50-day moving average | $183.67 | StockAnalysis snapshot as of July 10. Reclaiming this level would improve the short-term trend read. |
| 200-day moving average | $183.16 | StockAnalysis snapshot as of July 10. This nearby long-term reference is now resistance rather than support. |
| Momentum | RSI 39.68 | RSI was below neutral but not at a level that makes a reversal certain. |
| Volume | 20-day average 2.13 million shares | Compare rebound volume with this recent average because clinical-news moves can fade or accelerate on volume. |
| Volatility | $138.00 to $212.71 52-week range | The range and July trial reaction show that a defensive healthcare label does not eliminate single-stock volatility. |
| Invalidation | Close below $171 | A decisive close below the July 10 low would invalidate a short-term rebound framework and require a fresh chart review. |
AZN AI trading strategy
AZN AI Trading Strategy Framework
The AZN AI trading strategy is a rules-based research framework for a large biopharma stock in a clinical-news reset. It is not personal advice and should be refreshed with live prices, filings, trial disclosures, and position-sizing rules before any trade.
Trend-following setup
Wait for AZN to stabilize above the $171 to $172 support zone and then reclaim the $178 to $179 area. A later move above the $183 moving-average cluster with volume confirmation would be a stronger trend signal.
A close below $171 or a further material pipeline or guidance deterioration should invalidate the rebound setup.
Mean-reversion setup
If AZN holds above the July 10 low, compare the price reaction with the commercial importance of Wainua, the next earnings release, oncology sales, and any updated 2026 guidance before treating weakness as a valuation opportunity.
Do not average down without a predefined loss limit. Drug-development events can produce gaps that bypass ordinary stop assumptions.
Fundamental monitor
Track oncology revenue, Tagrisso, Imfinzi, Enhertu and Farxiga trends, late-stage readouts, 2026 revenue and core EPS guidance, R&D spending, free cash flow, net debt, China performance, and pricing policy.
Reduce confidence if sales growth or cash flow increasingly depend on acquisitions, price, or one franchise while clinical productivity and balance-sheet flexibility weaken.
Investment research summary
Four-master Research Compression
Business essence
AstraZeneca turns scientific discovery, clinical development, regulatory approvals, manufacturing, and specialist commercial access into recurring sales of branded medicines for serious disease.
Moat
The moat combines intellectual property, clinical evidence, regulatory know-how, physician trust, manufacturing capability, and global commercial reach. It is strongest in differentiated medicines and weakest when competition or patent expiry narrows differentiation.
Munger risk inversion
The thesis can fail if oncology growth slows, several late-stage programs miss, payers press prices, China conditions weaken, patent erosion accelerates, or debt and deal spending reduce owner cash flow.
Management
Management has built a bigger and more diversified growth portfolio, but shareholders should measure future quality through R&D returns, launch execution, business-development discipline, debt management, and candor around failed programs.
Industry trend
Aging populations, cancer treatment innovation, chronic disease, and precision medicine create long-term demand. The same industry also has binary clinical, regulatory, reimbursement, and patent-cycle risks.
Valuation and margin of safety
The July 9 price implied about 27x FY2025 reported EPS and 24.5x trailing free cash flow per share. Margin of safety depends on whether the pipeline and franchise mix can deliver the growth embedded in that valuation.
Source-backed data
AZN Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| AZN price and market capitalization | $178.49 July 9 close and $277.49 billion market cap | StockAnalysis AZN overview | July 10, 2026 |
| Market capitalization verification | $276.48 billion from $178.49 x 1.549 billion shares, a 0.36% difference from reported market cap | financial_rigor.py market cap verification | July 10, 2026 |
| FY2025 revenue | $58.739 billion, up 8.6% at actual exchange rates | AstraZeneca Annual Report 2025 and StockAnalysis cross-check | July 10, 2026 |
| FY2025 net income and reported EPS | $10.233 billion net income and $6.60 reported EPS | AstraZeneca Form 20-F and StockAnalysis cross-check | July 10, 2026 |
| FY2025 core EPS and dividend | $9.16 core EPS and $3.20 dividend per share | AstraZeneca Annual Report 2025 | July 10, 2026 |
| Q1 2026 revenue and adjusted EPS | $15.29 billion revenue and $2.58 adjusted EPS | AstraZeneca Q1 2026 results, reported by AP | July 10, 2026 |
| Cash and total debt | $7.68 billion cash and $34.03 billion debt at the latest quarter. FY2025 year-end cash was $5.7 billion, so the difference reflects a different reporting date. | StockAnalysis statistics and AstraZeneca Form 20-F | July 10, 2026 |
| Valuation check | 27.04x reported EPS, 5.84x book value, 24.48x trailing free cash flow per share, and 1.79% dividend yield | financial_rigor.py valuation verification | July 10, 2026 |
| Technical snapshot | 50-day average $183.67, 200-day average $183.16, RSI 39.68, and 20-day average volume 2.13 million shares | StockAnalysis statistics | July 10, 2026 |
Frequently Asked Questions
Read the ABBV AI stock analysisView AMGN AI stock forecastExplore MRK AI technical analysisCompare ideas in AI Stock PickerBuild a rules-based trading strategyScreen stocks with Pineify
This AZN AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, quote snapshots, and third-party data as of the stated cutoff date. They may be wrong, incomplete, or outdated after new earnings, trial results, approvals, pricing changes, market moves, or macro conditions.
Related Tools
Trading Strategy Builder
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Try it
Stock Screener
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Try it
AI Stock Picker & Screener
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
Try it